- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04808973
DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women (PREGNANCY)
A Pilot Study on the Efficacy of DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women Who Have Detectable Viral Load After 14 Weeks of Gestation
Study Overview
Status
Intervention / Treatment
Detailed Description
Main endpoints:
Primary:
-Proportion of women with undetectable HIV-1 plasma viral load at delivery
Secondary:
- Proportion of women switching therapy up to delivery
- Frequency of adverse events, regardless its relationship to the ARV drugs, for mothers and babies Frequency of MTCT
Inclusion criteria:
- Confirmed HIV infection
- No previous exposure to ARV drugs
- Plasma viral load ≥1,000 copies/ml
- Gestational age ≥ 14 and ≤ 28 weeks (checked by ultrasound)
- Age ≥ 15 years Exclusion criteria
- Presence of genotypic resistance mutations for 3TC or DTG
- Presence of active Hepatitis C
- Hepatitis B infection (a positive test for HBcore or HBsurface antibodies)
- Anemia (haemoglobin less than 8 g/dL);
- Need to use concomitant drugs with potentially relevant DDI, which require DTG dose adjustment (e.g., rifampin, carbamazepine, phenobarbital,phenytoin)
- Elevations in serum levels of alanine aminotransferase (ALT) greater than 5 times the upper limit of normal (ULN) or ALT >3xULN and bilirubin >1.5ULN (with >35% direct bilirubin);
- A history or clinical suspicion of unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hyperbilirubinaemia, oesophageal or gastric varices or persistent jaundice);
- Subjects with severe hepatic impairment (Class C) as determined by Child-Pugh classification
- Presence of severe pre-eclampsia, or other pregnancy related events such as renal or liver abnormalities (grade 2 or above proteinuria, elevation in serum creatinine CrCl<50 ml/min), total bilirubin, ALT or AST); After providing a written informed consent the woman will be prescribed a 2D regimen (3TC+DTG). They will be evaluated at baseline, and every 4 weeks, up to delivery.
Baseline Screening All consenting participants will have the following information and measurements collected at baseline.
- Demographics, including education.
- Documentation of HIV infection.
- CD4+ cell count and CD4%: one measurement within 60 days before inclusion.
- Targeted health history including date of first diagnosis of HIV infection, likely mode of HIV infection, history of non-AIDS events, history of sexually transmitted diseases (STIs) and gestational age.
- Brief clinical evaluation including weight, height, sitting blood pressure, pulse, and smoking status.
- Nadir CD4+ cell count and CD4% and maximum HIV RNA level available in the medical record from any time in the past.
- Findings from previous genotypic or other form of HIV resistance testing (such as virtual phenotype and/or phenotypic resistance testing), if performed and available.
- Concomitant medications, including any herbal/traditional remedies.
- Use of alcohol and recreational drugs.
- HIV transmission risk behavior assessment.
- HIV RNA measurement within the 4 previous weeks.
Additional laboratory assessments (participants should be asked to abstain from food, except water, for at least 8 hours prior to providing blood for glucose and lipid measurements):
- Complete blood count (CBC): hemoglobin, hematocrit, white blood cell count (WBC) with differential and platelets.
- CD8+ T-cell count and CD8%.
- Renal function: serum creatinine to estimate GFR.
- Liver function: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total bilirubin and albumin.
- Glucose and glycosylated Hb
- Lipids: total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides.
- Dipstick urinalysis for measurement of protein.
- Documentation of hepatitis B and C status: hepatitis B surface antigen, core antibody and surface antibody; hepatitis C antibody and, if available, genotype and viral load. Documented positive tests at any time in the past or documented negative tests in the 6 months before study entry may be used.
- HIV resistance testing Besides the routine medical evaluation they will be asked to provide a blood sample at every medical visit (every 4 weeks) to assess WBC, platelets count, hemoglobin, creatinine, liver enzymes, and fasting glucose / lipids. HIV-1 plasma viral load will also be assessed at the same time intervals. CD4/CD8+ cells count will be measured at baseline and after 24 and 36 weeks of gestation, or more frequently, at medical discretion.
According to the Brazilian MOH recommendations, babies will receive oral AZT for 4 weeks, if their mothers had a documented HIV RNA plasma viral load <1,000 copies/ml, in the third trimester of gestation. For those born from mothers presenting higher viral load, nevirapine will be added for the same period of time. In addition, they will be evaluated at delivery, after 2 and 6 weeks after the end of prophylaxis for HIV viral load measurements. Blood chemistry and hematology will be assessed 2 weeks after prophylaxis.16,17
Stopping criteria:
Participants will be excluded from study if the following conditions are met:
a) HIV-1 plasma viral load decay < 1 log compared with baseline values after 4 weeks of therapy, OR b) HIV-1 plasma viral load ≥ 1,000 copies/mL after 8 weeks of therapy Women will be recruited in a stepwise approach. Initially, 10 participants will be included, and followed up to the end of pregnancy. An interim analysis will evaluate the efficacy of the 2D ART regimen after the first 10 patients given birth. The study will be interrupted if 3 participants meet stopping criteria.
The second phase will start only if the number of women achieving the stopping criteria is ≤ 3 at completion of follow up for the first 10 participants, and will include 10 additional participants.
The study will have an estimated recruitment period of 4 months plus a maximum 6 months of follow up for the last enrolled patient, for each phase. Taken together, the first and second phases will require 20 months for enrollment and follow up. An interim analysis following the first phase will take one month, and the final analysis / writing reports is planned to last 3 months. Thus, the total duration of the study will be 24 months.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: CARLOS BRITES
- Phone Number: 71992329552
- Email: crbrites@gmail.com
Study Locations
-
-
BA
-
Salvador, BA, Brazil, 40110160
- Fundação Bahiana de Infectologia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Confirmed HIV infection
- No previous exposure to ARV drugs
- Plasma viral load ≥1,000 copies/ml
- Gestational age ≥ 14 and ≤ 28 weeks (checked by ultrasound)
- Age ≥ 15 years
Exclusion Criteria:
- Presence of genotypic resistance mutations for 3TC or DTG
- Presence of active Hepatitis C
- Hepatitis B infection (a positive test for HBcore or HBsurface antibodies)
- Anemia (haemoglobin less than 8 g/dL);
- Need to use concomitant drugs with potentially relevant DDI, which require DTG dose adjustment (e.g., rifampin, carbamazepine, phenobarbital,phenytoin)
- Elevations in serum levels of alanine aminotransferase (ALT) greater than 5 times the upper limit of normal (ULN) or ALT >3xULN and bilirubin >1.5ULN (with >35% direct bilirubin);
- A history or clinical suspicion of unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hyperbilirubinaemia, oesophageal or gastric varices or persistent jaundice);
- Subjects with severe hepatic impairment (Class C) as determined by Child-Pugh classification
- Presence of severe pre-eclampsia, or other pregnancy related events such as renal or liver abnormalities (grade 2 or above proteinuria, elevation in serum creatinine CrCl<50 ml/min), total bilirubin, ALT or AST)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lamivudine plus Dolutegravir in FDC
Single arm of 3TC+DTG for treatment of pregnant women with HIV infection
|
All participants will receive an ART regimen composed by Lamivudine plus Dolutegravir in a single pill (FDC)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
undetectable HIV-1 plasma viral load at delivery
Time Frame: 6 months
|
proportion of women achieving a plasma HIV RNA viral load below 50 copies at delivery
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
switch fo therapy up to delivery
Time Frame: 6 months
|
proportion of women switching therapy before delivey, any reason
|
6 months
|
frequency of adverse events for mothers and babies
Time Frame: 8 months
|
Frequency of adverse events, regardless its relationship to the ARV drugs, for mothers and babies
|
8 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Disease Attributes
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Infections
- Communicable Diseases
- Acquired Immunodeficiency Syndrome
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- HIV Integrase Inhibitors
- Integrase Inhibitors
- Lamivudine
- Dolutegravir
Other Study ID Numbers
- 213477
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Dolutegravir plus lamivudine in a FDC
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareCompleted
-
Shanghai Public Health Clinical CenterNot yet recruitingAcquired Immunodeficiency Syndrome
-
Fundación HuéspedViiV Healthcare; Federal University of BahiaRecruitingHIV-1-infectionBrazil, Argentina
-
ViiV HealthcareGlaxoSmithKlineCompletedHIV Infections | Infection, Human Immunodeficiency VirusUnited States, France, Spain, United Kingdom, Canada, Thailand, Italy, Portugal, Russian Federation, Mexico, Argentina, South Africa, Puerto Rico
-
Pedro CahnViiV HealthcareWithdrawn
-
ViiV HealthcareGlaxoSmithKlineCompletedHIV Infections | Infection, Human Immunodeficiency VirusUnited States, Argentina, Spain, Germany, Belgium, Australia, Canada, United Kingdom, Italy, Romania, Taiwan, Russian Federation, Mexico, France, Switzerland, Peru, Poland, Portugal
-
Philip GrantWithdrawnHIV/AIDS | Osteopenia | HIV-1-infectionUnited States
-
ViiV HealthcareGlaxoSmithKline; PPDCompletedHIV Infections | Infection, Human Immunodeficiency VirusTaiwan, France, Germany, Belgium, United States, Canada, Netherlands, Spain, Korea, Republic of, Italy, Australia, United Kingdom, Russian Federation, Portugal, Argentina, South Africa, Romania, Mexico
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletedHealthy Subjects | Infection, Human Immunodeficiency VirusUnited States